These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33022393)

  • 1. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: A review.
    Nasser MF; Gandhi S; Siegel RJ; Rader F
    Heart Rhythm; 2021 Feb; 18(2):297-302. PubMed ID: 33022393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review.
    Oliphant CS; McCullough J; Hashim T; Khouzam RN
    Future Cardiol; 2014 Mar; 10(2):229-33. PubMed ID: 24762250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.
    Lee HJ; Kim HK; Jung JH; Han KD; Lee H; Park JB; Kim HM; Kim YJ; Ommen SR
    Stroke; 2019 Sep; 50(9):2582-2586. PubMed ID: 31340730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
    Nasser MF; Jabri A; Gandhi S; Rader F
    Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic cardiomyopathy: a real risk factor for stroke.
    Badawi RA; Seetharaman S; Birns J
    Scott Med J; 2012 Feb; 57(1):60. PubMed ID: 22194403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 9. Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?
    Frontera A; Wilson DG; Sekhon H; Duncan ER; Thomas G
    Clin Res Cardiol; 2015 Oct; 104(10):799-802. PubMed ID: 26133157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism.
    Chan NC; Eikelboom JW
    Blood; 2019 May; 133(21):2269-2278. PubMed ID: 30926593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation.
    Tsuda T; Hayashi K; Fujino N; Konno T; Tada H; Nomura A; Tanaka Y; Sakata K; Furusho H; Takamura M; Kawashiri MA; Yamagishi M;
    Heart Rhythm; 2019 Jun; 16(6):829-837. PubMed ID: 30503962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
    Hsu JC; Huang YT; Lin LY
    Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
    Cove CL; Hylek EM
    J Am Heart Assoc; 2013 Oct; 2(5):e000136. PubMed ID: 24152980
    [No Abstract]   [Full Text] [Related]  

  • 14. The risk factors for thromboembolism in nonvalvular atrial fibrillation and CHADS2 scoring in Japan.
    Aihara M; Guyatt G
    Circ J; 2007 Dec; 71(12):1999; author reply 2000. PubMed ID: 18037762
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
    JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy.
    Oliveri F; Pepe A; Bongiorno A; Fasolino A; Gentile FR; Schirinzi S; Colombo D; Breviario F; Greco A; Turco A; Acquaro M; Tua L; Scelsi L; Ghio S
    Am J Cardiovasc Drugs; 2023 May; 23(3):269-276. PubMed ID: 37061614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboembolic Events in Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation During New Oral Anticoagulant Therapy.
    An M; Park YM; Seo J; Lee J; Jang AY; Kang WC; Chung WJ; Choi IS
    Anatol J Cardiol; 2023 Sep; 27(10):608-610. PubMed ID: 37599635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.